Reunion Neuroscience is a venture backed clinical-stage biopharmaceutical company developing novel therapeutics for neuropsychiatric disorders.

Reunion Neuroscience

Reunion Neuroscience is committed to innovating therapeutic solutions to treat mental health conditions through the development of novel psychedelic compounds. NASDAQ:REUN 


We are thrilled to share our recent article in Psychiatric Times highlighting the clinical development of RE104, a proprietary, serotonergic #psychedelic drug candidate for underserved #mentalhealth disorders, beginning with #postpartumdepression. Thank you to Reunion team members, Robert Alexander, Jasna Hocevar-Trnka, Nathan Bryson, PhD and Beatrix Taylor for their incredible work on this article: https://bit.ly/4eA0eZn

Reunion now has the fuel on board to move boldly forward with RE104 into Phase 2 programs in postpartum depression and adjustment disorder in cancer patients.  Thank you very much to our top tier investing syndicate for linking arms with us to help bring forward a new and meaningful treatment option to address the worldwide mental health crisis.  Onward!

Looking forward to SXSW and speaking about new treatments for postpartum depression with Daniel Goldberg Greg Mayes and Melissa Whippo!

We are excited to announce the publication of the results of preclinical studies in ACS Chemical Neuroscience demonstrating the potential of RE104 for development in depressive disorders. Reunion is advancing RE104, a proprietary, clinical-stage serotonergic #psychedelic drug candidate designed as a safe, fast-acting, short duration therapy for underserved #mentalhealth disorders, beginning with #postpartumdepression. Read the press release: https://bit.ly/3wFJkY4

#MMHWeek2024 is an opportunity to raise awareness of #MaternalMentalHealth as a significant unmet need. Mental health conditions are the leading underlying cause of pregnancy-related death, with preventable deaths accounting for more than 80 percent. In our mission to address the worldwide mental health crisis, Reunion is advancing RE104 for underserved #mentalhealth disorders, beginning with #postpartumdepression.

REUN

COM:REUNIONNEURO

Reunion Neuroscience

market

industry

website

linkedin

investor of

Metrics